Daniel Chang

Publications

• Dosimetric analysis of organs at risk during expiratory gating in stereotactic body radiation therapy for pancreatic cancer. Taniguchi CM, Murphy JD, Eclov N, Atwood TF, Kielar KN, Christman-Skieller C, Mok E, Xing L, Koong AC, Chang DT. Int J Radiat Oncol Biol Phys. 2013; 85 (4): 1090-5
• Long-term outcomes of surgery followed by radiation therapy for minor salivary gland carcinomas. Zeidan YH, Shultz DB, Murphy JD, An Y, Chan C, Kaplan MJ, Colevas AD, Kong C, Chang DT, Le QT. Laryngoscope. 2013
• Metabolic tumor volume predicts disease progression and survival in patients with squamous cell carcinoma of the anal canal. Bazan JG, Koong AC, Kapp DS, Quon A, Graves EE, Loo BW, Chang DT. J Nucl Med. 2013; 54 (1): 27-32
• Oncology scan-treatment, consequences, and genomics in gastrointestinal cancer. Willett CG, Chang DT, Czito BG, Meyer J, Wo J. Int J Radiat Oncol Biol Phys. 2013; 86 (1): 1-3
• Radiotherapy for nonadenoid cystic carcinomas of major salivary glands. Chung MP, Tang C, Chan C, Hara WY, Loo BW, Kaplan MJ, Fischbein N, Le QT, Chang DT. Am J Otolaryngol. 2013
• Seventh edition (2010) of the AJCC/UICC staging system for gastric adenocarcinoma: is there room for improvement? Patel MI, Rhoads KF, Ma Y, Ford JM, Visser BC, Kunz PL, Fisher GA, Chang DT, Koong A, Norton JA, Poultsides GA. Ann Surg Oncol. 2013; 20 (5): 1631-8
• Signet Ring Cell Colorectal Carcinoma: A Distinct Subset of Mucin-poor Microsatellite-stable Signet Ring Cell Carcinoma Associated With Dismal Prognosis. Hartman DJ, Nikiforova MN, Chang DT, Chu E, Bahary N, Brand RE, Zureikat AH, Zeh HJ, Choudry H, Pai RK. Am J Surg Pathol. 2013
• Esophageal tolerance to high-dose stereotactic ablative radiotherapy. Abelson JA, Murphy JD, Loo BW, Chang DT, Daly ME, Wiegner EA, Hancock S, Chang SD, Le QT, Soltys SG, Gibbs IC. Dis Esophagus. 2012 Sep-Oct; 25 (7): 623-9
• BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Pai RK, Jayachandran P, Koong AC, Chang DT, Kwok S, Ma L, Arber DA, Balise RR, Tubbs RR, Shadrach B, Pai RK. Am J Surg Pathol. 2012; 36 (5): 744-52
• Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. Chang DT, Pai RK, Rybicki LA, Dimaio MA, Limaye M, Jayachandran P, Koong AC, Kunz PA, Fisher GA, Ford JM, Welton M, Shelton A, Ma L, Arber DA, Pai RK. Mod Pathol. 2012; 25 (8): 1128-39
• Combined modality therapy for rectal cancer: the relative value of posttreatment versus pretreatment CEA as a prognostic marker for disease recurrence. Song S, Hong JC, McDonnell SE, Koong AC, Minsky BD, Chang DT, Liauw SL. Ann Surg Oncol. 2012; 19 (8): 2471-6
• Combined-modality Therapy for Rectal Cancer: Analysis of Potential Differences in Disease Presentation, Treatment Adherence, and Treatment Outcome According to Race. Tonlaar N, Song S, Hong JC, Minsky BD, Chang DT, Polite BN, Liauw SL. Am J Clin Oncol. 2012
• Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer. Murphy JD, Chang DT, Abelson J, Daly ME, Yeung HN, Nelson LM, Koong AC. Cancer. 2012; 118 (4): 1119-29
• HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Kunz PL, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR, Bangs CD, Cherry AM, Pai RK. Appl Immunohistochem Mol Morphol. 2012; 20 (1): 13-24
• Intensity-modulated radiotherapy for pancreatic adenocarcinoma. Abelson JA, Murphy JD, Minn AY, Chung M, Fisher GA, Ford JM, Kunz P, Norton JA, Visser BC, Poultsides GA, Koong AC, Chang DT. Int J Radiat Oncol Biol Phys. 2012; 82 (4): e595-601
• Intensity-modulated radiotherapy for tumors of the nasal cavity and paranasal sinuses: clinical outcomes and patterns of failure. Wiegner EA, Daly ME, Murphy JD, Abelson J, Chapman CH, Chung M, Yu Y, Colevas AD, Kaplan MJ, Fischbein N, Le QT, Chang DT. Int J Radiat Oncol Biol Phys. 2012; 83 (1): 243-51
• Intrafraction verification of gated RapidArc by using beam-level kilovoltage X-ray images. Li R, Mok E, Chang DT, Daly M, Loo BW, Diehn M, Le QT, Koong A, Xing L. Int J Radiat Oncol Biol Phys. 2012; 83 (5): e709-15
• Modern radiation therapy techniques for pancreatic cancer. Trakul N, Koong AC, Maxim PG, Chang DT. Gastroenterol Clin North Am. 2012; 41 (1): 223-35
• Normal tissue complication probability modeling of acute hematologic toxicity in patients treated with intensity-modulated radiation therapy for squamous cell carcinoma of the anal canal. Bazan JG, Luxton G, Mok EC, Koong AC, Chang DT. Int J Radiat Oncol Biol Phys. 2012; 84 (3): 700-6
• Orthovoltage intraoperative radiotherapy for locally advanced and recurrent colorectal cancer. Daly ME, Kapp DS, Maxim PG, Welton ML, Tran PT, Koong AC, Chang DT. Dis Colon Rectum. 2012; 55 (6): 695-702
• Positron emission tomography for predicting pathologic response after neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Chennupati SK, Quon A, Kamaya A, Pai RK, La T, Krakow TE, Graves E, Koong AC, Chang DT. Am J Clin Oncol. 2012; 35 (4): 334-9
• Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer. Jayachandran P, Pai RK, Quon A, Graves E, Krakow TE, La T, Loo BW, Koong AC, Chang DT. Int J Radiat Oncol Biol Phys. 2012; 84 (2): 471-7
• Prognostic value of metabolic tumor volume and velocity in predicting head-and-neck cancer outcomes. Chu KP, Murphy JD, La TH, Krakow TE, Iagaru A, Graves EE, Hsu A, Maxim PG, Loo B, Chang DT, Le QT. Int J Radiat Oncol Biol Phys. 2012; 83 (5): 1521-7
• A rare case of an aldosterone secreting metastatic adrenocortical carcinoma and papillary thyroid carcinoma in a 31-year-old male. Wanta SM, Basina M, Chang SD, Chang DT, Ford JM, Greco R, Kingham K, Merritt RE, Kunz PL. Rare Tumors. 2011; 3 (4): e45
• Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Bazan JG, Hara W, Hsu A, Kunz PA, Ford J, Fisher GA, Welton ML, Shelton A, Kapp DS, Koong AC, Goodman KA, Chang DT. Cancer. 2011; 117 (15): 3342-51
• Intensity-modulated radiotherapy for locally advanced cancers of the larynx and hypopharynx. Daly ME, Le QT, Jain AK, Maxim PG, Hsu A, Loo BW, Kaplan MJ, Fischbein NJ, Colevas AD, Pinto H, Chang DT. Head Neck. 2011; 33 (1): 103-11
• Intensity-modulated radiotherapy for oral cavity squamous cell carcinoma: patterns of failure and predictors of local control. Daly ME, Le QT, Kozak MM, Maxim PG, Murphy JD, Hsu A, Loo BW, Kaplan MJ, Fischbein NJ, Chang DT. Int J Radiat Oncol Biol Phys. 2011; 80 (5): 1412-22
• Pattern of lymph node involvement and prognosis in pancreatic adenocarcinoma: direct lymph node invasion has similar survival to node-negative disease. Pai RK, Beck AH, Mitchem J, Linehan DC, Chang DT, Norton JA, Pai RK. Am J Surg Pathol. 2011; 35 (2): 228-34
• Prospective randomized double-blind pilot study of site-specific consensus atlas implementation for rectal cancer target volume delineation in the cooperative group setting. Fuller CD, Nijkamp J, Duppen JC, Rasch CR, Thomas CR, Wang SJ, Okunieff P, Jones WE, Baseman D, Patel S, Demandante CG, Harris AM, Smith BD, Katz AW, McGann C, Harper JL, Chang DT, Smalley S, Marshall DT, Goodman KA, Papanikolaou N, Kachnic LA. Int J Radiat Oncol Biol Phys. 2011; 79 (2): 481-9
• Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Schellenberg D, Kim J, Christman-Skieller C, Chun CL, Columbo LA, Ford JM, Fisher GA, Kunz PL, Van Dam J, Quon A, Desser TS, Norton J, Hsu A, Maxim PG, Xing L, Goodman KA, Chang DT, Koong AC. Int J Radiat Oncol Biol Phys. 2011; 81 (1): 181-8
• Stereotactic body radiation therapy for gastrointestinal malignancies. Minn AY, Koong AC, Chang DT. Front Radiat Ther Oncol. 2011: 43 412-27
• Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Chang DT, Swaminath A, Kozak M, Weintraub J, Koong AC, Kim J, Dinniwell R, Brierley J, Kavanagh BD, Dawson LA, Schefter TE. Cancer. 2011; 117 (17): 4060-9
• 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Schellenberg D, Quon A, Minn AY, Graves EE, Kunz P, Ford JM, Fisher GA, Goodman KA, Koong AC, Chang DT. Int J Radiat Oncol Biol Phys. 2010; 77 (5): 1420-5
• A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer. Murphy JD, Christman-Skieller C, Kim J, Dieterich S, Chang DT, Koong AC. Int J Radiat Oncol Biol Phys. 2010; 78 (5): 1420-6
• Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer. Minn AY, Hsu A, La T, Kunz P, Fisher GA, Ford JM, Norton JA, Visser B, Goodman KA, Koong AC, Chang DT. Cancer. 2010; 116 (16): 3943-52
• EUS-guided gold fiducial insertion for image-guided radiation therapy of pancreatic cancer: 50 successful cases without fluoroscopy. Park WG, Yan BM, Schellenberg D, Kim J, Chang DT, Koong A, Patalano C, Van Dam J. Gastrointest Endosc. 2010; 71 (3): 513-8
• Expression of p16(INK4A) but not hypoxia markers or poly adenosine diphosphate-ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma. Chang DT, Chapman CH, Norton JA, Visser B, Fisher GA, Kunz P, Ford JM, Koong AC, Pai RK. Cancer. 2010; 116 (22): 5179-87
• Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: clinical outcomes and patterns of failure. Daly ME, Le QT, Maxim PG, Loo BW, Kaplan MJ, Fischbein NJ, Pinto H, Chang DT. Int J Radiat Oncol Biol Phys. 2010; 76 (5): 1339-46
• Interfractional uncertainty in the treatment of pancreatic cancer with radiation. Jayachandran P, Minn AY, Van Dam J, Norton JA, Koong AC, Chang DT. Int J Radiat Oncol Biol Phys. 2010; 76 (2): 603-7
• Multimodality treatment with intensity modulated radiation therapy for esophageal cancer. La TH, Minn AY, Su Z, Fisher GA, Ford JM, Kunz P, Goodman KA, Koong AC, Chang DT. Dis Esophagus. 2010; 23 (4): 300-8
• Orthovoltage intraoperative radiation therapy for pancreatic adenocarcinoma. Bachireddy P, Tseng D, Horoschak M, Chang DT, Koong AC, Kapp DS, Tran PT. Radiat Oncol. 2010: 5 105
• Pathological response after chemoradiation for T3 rectal cancer. Chennupati SK, Kamaya A, Fisher GA, Ford JM, Kunz P, Itakura H, Welton ML, Shelton A, Van Dam J, Koong AC, Chang DT. Colorectal Dis. 2010; 12 (7 Online): e24-30
• Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. Chang ST, Zahn JM, Horecka J, Kunz PL, Ford JM, Fisher GA, Le QT, Chang DT, Ji H, Koong AC. J Transl Med. 2009: 7 105
• Long-term outcomes for stage I-II aggressive non-Hodgkin lymphoma of Waldeyer's ring. Chang DT, Mendenhall NP, Lynch JW, Morris CG, Olivier KR. Am J Clin Oncol. 2009; 32 (3): 233-7
• Percutaneous implantation of fiducial markers for imaging-guided radiation therapy. Kothary N, Dieterich S, Louie JD, Chang DT, Hofmann LV, Sze DY. AJR Am J Roentgenol. 2009; 192 (4): 1090-6
• Pharmacologically increased tumor hypoxia can be measured by 18F-Fluoroazomycin arabinoside positron emission tomography and enhances tumor response to hypoxic cytotoxin PR-104. Cairns RA, Bennewith KL, Graves EE, Giaccia AJ, Chang DT, Denko NC. Clin Cancer Res. 2009; 15 (23): 7170-4
• Safety and efficacy of percutaneous fiducial marker implantation for image-guided radiation therapy. Kothary N, Heit JJ, Louie JD, Kuo WT, Loo BW, Koong A, Chang DT, Hovsepian D, Sze DY, Hofmann LV. J Vasc Interv Radiol. 2009; 20 (2): 235-9
• Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Chang DT, Schellenberg D, Shen J, Kim J, Goodman KA, Fisher GA, Ford JM, Desser T, Quon A, Koong AC. Cancer. 2009; 115 (3): 665-72
• Treatment of esophageal cancer based on histology: a surveillance epidemiology and end results analysis. Chang DT, Chapman C, Shen J, Su Z, Koong AC. Am J Clin Oncol. 2009; 32 (4): 405-10
• Xerostomia in long-term survivors of aggressive non-Hodgkin's lymphoma of Waldeyer's ring: a potential role for parotid-sparing techniques? Chang DT, Amdur RJ, Pacholke H, Mendenhall NP, Morris CG, Byer GA, Olivier KR. Am J Clin Oncol. 2009; 32 (2): 145-9
• Do pre-irradiation dental extractions reduce the risk of osteoradionecrosis of the mandible? Chang DT, Sandow PR, Morris CG, Hollander R, Scarborough L, Amdur RJ, Mendenhall WM. Head Neck. 2007; 29 (6): 528-36
• Long-term outcomes in breast cancer patients with ten or more positive axillary nodes treated with combined-modality therapy: the importance of radiation field selection. Chang DT, Feigenberg SJ, Indelicato DJ, Morris CG, Lightsey J, Grobmyer SR, Copeland EM, Mendenhall NP. Int J Radiat Oncol Biol Phys. 2007; 67 (4): 1043-51
• Predicting changes in dose distribution to tumor and normal tissue when correcting for heterogeneity in radiotherapy for lung cancer. Chang D, Liu C, Dempsey JF, Palta JR, Kopea J, Louis D, Morris C, Chopra R, Olivier KR. Am J Clin Oncol. 2007; 30 (1): 57-62
• Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation. Chang DT, Amdur RJ, Morris CG, Mendenhall WM. Int J Radiat Oncol Biol Phys. 2006; 66 (4): 1051-5
• The impact of heterogeneity correction on dosimetric parameters that predict for radiation pneumonitis. Chang DT, Olivier KR, Morris CG, Liu C, Dempsey JF, Benda RK, Palta JR. Int J Radiat Oncol Biol Phys. 2006; 65 (1): 125-31
• Merkel cell carcinoma of the skin with leptomeningeal metastases. Chang DT, Mancuso AA, Riggs CE, Mendenhall WM. Am J Otolaryngol. 2005 May-Jun; 26 (3): 210-3
• Re-examining the role of elective nodal irradiation: finding ways to maximize the therapeutic ratio. Chang DT, Zlotecki RA, Olivier KR. Am J Clin Oncol. 2005; 28 (6): 597-602
• Role of p53 in cell cycle regulation and apoptosis following exposure to proteasome inhibitors. Chen F, Chang D, Goh M, Klibanov SA, Ljungman M. Cell Growth Differ. 2000; 11 (5): 239-46
• Dose-dependent effects of DNA-damaging agents on p53-mediated cell cycle arrest. Chang D, Chen F, Zhang F, McKay BC, Ljungman M. Cell Growth Differ. 1999; 10 (3): 155-62